COVID-19 outbreak is associated with the generation of many types of infectious wastes, including infected masks, gloves and other protective equipment, together with a higher volume of general waste of the same nature.
Globally, the cancer burden is rising, exerting significant strain on
populations and health systems at all levels of income. There are
concerted efforts towards enhancing access to comprehensive
cancer prevention and control initiatives.
Ramped-up cancer services could save 7 million lives over the next decade—and addressing huge service gaps between rich and poor countries is key to success, according to this report.
In 2019, over 90% of high-income countries reported that comprehensive cancer treatment services were available... through the public health system, compared to fewer than 15% of low-income countries, according to WHO.
But poorer countries can make substantial strides with a universal health coverage approach and use of the latest science to meet their particular needs.
The report lays out proven ways to prevent new cancer cases without breaking the bank, including tobacco-control measures and vaccines that protect against common cancers.
more
Refugee protection in the country is provided within the framework of these international and national refugee laws as well as the core international human rights treaties that have been ratified by the country. Continued insecurity within neighbouring states has resulted in sustained refugee moveme...nts, either directly as a result of internal conflict and human rights abuses or as a result of conflict related to competition for scare natural resources and drought related food insecurity.
more
Developed by the HHS Panel on Treatment of Pregnant Women with HIV Infection and Prevention of Perinatal Transmission—
A Working Group of the Office of AIDS Research Advisory Council (OARAC)
Accessed: 12.02.2020
Identification and initial management of cases. Clinical guidance
The purpose of this document is to provide relevant information and guidelines on
coronavirus outbreaks – and in particular the novel coronavirus SARS-CoV-2 and the
diseases it produces, COVID-19 – for pharmacists and the pharmacy workforce, both in a
primary care context (i.e. community phar...macies and primary healthcare facilities) and in
hospital settings, as well as for pharmacists working as clinical biologists in medical
analysis laboratories, for example, as clinical biologists, and offer a set of references that
may be consulted for more informationstor
more
Evaluating the Return on Investment of Scaling Up Treatment for Depression, Anxiety, and Psychosis